Avience Biomedi.
Avience Biomedi. Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
4 of 5 strong
The short version
Targeting at least 60% growth in FY27, with potential to exceed this level. The company targets at least 60% revenue growth in FY27, potentially exceeding ₹100 crore in revenue.
From Avience Biomedi.'s Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Targeting at least 60% growth in FY27, with potential to exceed this level.
- Expecting revenue to exceed ₹100 crore during FY27, supported by a ₹47 crore order.
- For FY28, broad revenue aspiration is approximately ₹160–165 crore.
- New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals.
- Expansion into new territories, beyond current Delhi NCR and eastern Uttar Pradesh regions, including Uttarakhand.
- Increase in in-house manufacturing aiming to shift turnover mix from current ~30:70 (manufacturing:trading) to closer to 50:50.
2 more points from Avience Biomedi.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Avience Biomedi. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- A new manufacturing facility is substantially complete, with remaining work expected by September 2026 and manufacturing starting from October 2026.
- The new unit will provide increased scale, enabling participation in larger tenders and government business.
- The facility is designed considering WHO prequalification requirements to support exports.
- The new facility has a capacity to support peak revenue of approximately ₹250–265 crore.
- Plans to discontinue the existing rented manufacturing facility post transition of 3–4 months after the new unit stabilizes.
- The company targets shifting its manufacturing-to-trading revenue mix closer to 50:50 as in-house manufacturing scales up.
2 more points from Avience Biomedi.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Avience Biomedi. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Company currently has an order of approximately ₹47 crore in hand.
- This large order notably relates to Uttarakhand, expanding the Company's presence into new territory.
- The ₹47–50 crore order includes a significant equipment component.
- With the new manufacturing facility operational, the Company can now pursue larger private and government tenders which were previously limited due to scale.
- Government tenders typically require delivery within 45–60 days to avoid penalties or blacklisting.
2 more points from Avience Biomedi.'s call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Healthcare Equipment & Supplies this season
- Fischer Medical Ventures Ltd (Q1 FY27)
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…
- Molbio Diagnosti (Q1 FY27)
Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment. Key…
- QMS Medical Allied Services Ltd (Q1 FY27)
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
- Laxmi Dental Ltd (Q1 FY27)
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
Arthneeti Pro · Annual
Avience Biomedi. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Avience Biomedi. Q1 FY27 results?
Targeting at least 60% growth in FY27, with potential to exceed this level. The company targets at least 60% revenue growth in FY27, potentially exceeding ₹100 crore in revenue.
What is Avience Biomedi. share price analysis?
Avience Biomedi. currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 17.4 with a market cap of ₹152 Cr. Investors should review the full earnings analysis for detailed insights.
Is Avience Biomedi. planning capital expenditure?
A new manufacturing facility is substantially complete, with remaining work expected by September 2026 and manufacturing starting from October 2026.
Keep Avience Biomedi. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.